Pelosof L, et al. - In a single, randomized, placebo-controlled trial (RESORCE), the benefit-to-risk evaluation of regorafenib was carried out in patients with advanced hepatocellular carcinoma (HCC) who had previously been treated with sorafenib. Improved survival and acceptable toxicity were demonstrated. A favorable benefit-to-risk evaluation of regorafenib led to its approval as a treatment option for patients with advanced HCC.